Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Genetically Encoded Frankenbody Lights Up Live Cell Imaging

Stitching together complementarity-determining regions (CDRs) and single-chain variable fragment (scFv) scaffolds, scientists based at Colorado State University and Tokyo Institute of Technology have built what they call a frankenbody. This hybrid creation can

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Stitching together complementarity-determining regions (CDRs) and single-chain variable fragment (scFv) scaffolds, scientists based at Colorado State University and Tokyo Institute of Technology have built what they call a frankenbody. This hybrid creation can bind a common epitope tag, the linear HA epitope tag. Most notably, it works in living systems, where it can add distinctive labels to diverse proteins. In a recent study, it enabled the multicolor visualization of HA-tagged nuclear, cytoplasmic, membrane, and mitochondrial proteins.

For many decades, scientists have cleverly exploited the selective tagging of natural antibodies to engineer antibody-based probes that can be used to purify and study different types of proteins within cells. One tried and true technique, epitope tagging, involves fusing an epitope to a protein of interest and using fluorescently labeled antibodies to make those proteins visible—but seldom in fixed, dead cells.

Now, a new approach has been developed by cross-disciplinary team of researchers. Some of the researchers come from a lab led by Colorado State University’s Tim Stasevich; others, from a lab led by Tokyo Tech’s Hiroshi Kimura. Together, they have developed a genetically encoded probe expressly designed to work in living cells.

Details appeared July 3 in the journal Nature Communications, in an article titled, “A genetically encoded probe for imaging nascent and mature HA-tagged proteins in vivo.”

“[We used the HA frankenbody [to track] single HA-tagged histones in U2OS cells and single mRNA translation dynamics in both U2OS cells and neurons,” the article’s authors wrote. “Together with the SunTag, we also track two mRNA species simultaneously to demonstrate comparative single-molecule studies of translation can now be done with genetically encoded tools alone. Finally, we use the HA frankenbody to precisely quantify the expression of HA-tagged proteins in developing zebrafish embryos.”

Like stitching new limbs on a body, the scientists have taken the binding regions of a normal antibody, the “sticky parts,” and grafted them to a different scaffold that remains stable in live cells but retains the specificity of the antibody.

“We’re interested in intracellular antibodies because you can use them as imaging reagents in a live cell,” said Stasevich. “You don’t need a tag, like a green fluorescent protein, because instead you have this fluorescent antibody that will bind to your protein that you want to visualize.”

The new probe would be a useful complement to the green fluorescent protein, a widespread biochemistry tool and subject of a Nobel Prize that involves genetically fusing a light-up green tag to a protein of interest. However, the GFP is limited by its relatively large size and the time it takes to fluoresce; with the CSU researchers’ new probe, the tag is smaller and becomes fluorescent faster, so the “birth” of a protein of interest can be captured in real time.

With the goal of making their tool immediately useful, the scientists designed their probe to work with the classic HA tag. HA is a widely used small linear epitope tag that’s derived from a portion of the human influenza virus protein hemagglutinin.

“For the longest time, people have been looking at HA-tagged proteins in fixed, dead cells,” Stasevich said. “Now we can image the dynamics of those proteins in live cells.”

The scientists in Stasevich’s lab are particularly interested in studying RNA translation, and they plan to use their new system to more easily design new RNA imaging experiments.

According to Ning Zhao, a postdoctoral research in Stasevich’s lab and the current study’s first author, the HA tag is tiny—a chain of just nine amino acids—and the probe is genetically encoded on a plasmid that can be easily transferred into a cell. This is in contrast to traditional antibodies, which can cost a lab several hundreds of dollars per order, suffer from lot-to-lot variability, and are difficult to get into cells. The new probe from Stasevich’s team, therefore, provides a low-cost solution for protein and RNA translation imaging.

“We have several new imaging reagents in the works that build off of this success,” Stasevich pointed out. “So, I see great things ahead.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →